American International Group, Inc. Poseida Therapeutics, Inc. Transaction History

American International Group, Inc.

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	SELL	$2.76 - $4.13 $794 - $1,189	-288 Reduced 0.85%	33,494 $106,000
Q4 2023 Feb 13, 2024	SELL	$1.83 - $3.51 $248 - $477	-136 Reduced 0.4%	33,782 $113,000
Q3 2023 Nov 13, 2023	BUY	$1.62 - $2.79 $1,953 - $3,364	1,206 Added 3.69%	33,918 $80,000
Q2 2023 Aug 04, 2023	BUY	$1.66 - $3.4 $54,301 - $111,220	32,712 New	32,712 $57,000
Q2 2022 Aug 12, 2022	SELL	$1.87 - $5.0 $26,701 - $71,395	-14,279 Closed	0 $0
Q1 2022 May 13, 2022	SELL	$3.22 - $7.04 $3,239 - $7,082	-1,006 Reduced 6.58%	14,279 $64,000
Q4 2021 Feb 11, 2022	SELL	$6.23 - $7.6 $2,840 - $3,465	-456 Reduced 2.9%	15,285 $104,000
Q3 2021 Nov 12, 2021	SELL	$7.09 - $10.71 $2,658 - $4,016	-375 Reduced 2.33%	15,741 $115,000
Q2 2021 Aug 13, 2021	SELL	$7.96 - $10.07 $25,320 - $32,032	-3,181 Reduced 16.48%	16,116 $161,000
Q1 2021 May 07, 2021	BUY	$8.51 - $11.91 $97,796 - $136,869	11,492 Added 147.24%	19,297 $184,000
Q4 2020 Feb 12, 2021	SELL	$8.29 - $11.7 $1,865 - $2,632	-225 Reduced 2.8%	7,805 $86,000
Q3 2020 Nov 04, 2020	BUY	$8.09 - $16.25 $64,962 - $130,487	8,030 New	8,030 $71,000

38.1M

417K

42.7K

Ticker PSTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 85,775,600
Market Cap $245M
Description
Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-101, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant ...

Get notified when there are updates to the investment portfolio of American International Group, Inc., based on Form 13F filings with the SEC.

Stay updated on American International Group, Inc. with notifications on news.